ea0041gp110 | Endocrine Tumours | ECE2016
Pani Fabiana
, Orgiano Laura
, Boi Francesco
, Massa Elena
, Madeddu Clelia
, Pusceddu Valeria
, Scartozzi Mario
, Mariotti Stefano
Introduction: Regorafenib, a Tyrosine kinase inhibitor (TKI) recently approved for the treatment of metastatic colorectal cancer patients previously treated with fluoropyrimidine-based chemotherapy, VEGF and EGFR inhibitors, may, like others TKIs produce hypothyroidism, but this effect has not been systematically evaluated so far.Description of methods: Prospective evaluation of thyroid function, autoimmunity and morphology during treatment with Regorafe...